Biofourmis

Ross Armstrong is the CEO of Biofourmis. To contact Ross Armstrong email at [email protected] or [email protected]. Or you may call 214-563-4700

The decision makers in Biofourmis are Andrew Slotnick, Andy Chung, Brian Murphy, etc. Click to Find Biofourmis decision makers emails.

Biofourmis provides a comprehensive suite of remote patient management (RPM) solutions that leverage AI-driven technology to monitor patients' health in real-time. The platform collects and analyzes over 120 biomarkers, allowing healthcare providers to detect shifts in a patient's condition promptly. This service is particularly beneficial for managing chronic diseases, post-acute care, and ensuring continuous monitoring of patients in a home setting.

Biofourmis employs advanced artificial intelligence algorithms to analyze vast amounts of health data collected from patients. By processing over 120 biomarkers in real-time, the AI identifies patterns and potential health risks, enabling proactive interventions. This technology enhances decision-making for healthcare providers and improves patient outcomes by facilitating timely care adjustments based on individual health trends.

Biofourmis supports a variety of industries, including oncology, cardiovascular care, pulmonology, and digital therapeutics. Their solutions are designed to enhance patient care across these sectors by providing tools for remote monitoring, decentralized clinical trials, and personalized health management. This broad applicability allows healthcare providers to implement Biofourmis' technology in diverse clinical settings, improving patient engagement and outcomes.

Digital therapeutics play a crucial role in Biofourmis' approach to patient care. These evidence-based therapeutic interventions are delivered through software to prevent, manage, or treat medical conditions. Biofourmis integrates digital therapeutics into its RPM solutions, allowing for personalized treatment plans that adapt based on real-time health data. This integration supports better adherence to treatment protocols and enhances overall patient health management.

Yes, Biofourmis' solutions are well-suited for decentralized clinical trials. The company's technology enables remote monitoring of trial participants, collecting real-time data on various health metrics. This capability allows researchers to conduct trials more efficiently, reducing the need for in-person visits while maintaining high data integrity. By facilitating remote patient engagement, Biofourmis helps streamline the clinical trial process and improve participant retention.

Biofourmis prioritizes patient privacy and data security by implementing robust security measures in compliance with industry standards and regulations, such as HIPAA. The platform employs encryption, secure data storage, and strict access controls to protect sensitive health information. Additionally, Biofourmis conducts regular security audits and risk assessments to ensure the ongoing safety of patient data, fostering trust among users and healthcare providers.